NXTE - ETF AI Analysis
Top Page
AXS Green Alpha ETF (NXTE)
NXTE, the AXS Green Alpha ETF, appears to be a solid but not top-tier fund, supported by strong core holdings like TSM and ASML, which benefit from robust financial performance, positive growth prospects in advanced technologies and AI, and favorable technical trends. Additional strengths from companies such as AMAT, LRCX, IBM, and QCOM further bolster the fund, though weaker names like Moderna and Crispr Therapeutics, with profitability and momentum challenges, drag on the overall quality. The main risk factor is the fund’s heavy concentration in a small group of semiconductor and advanced tech companies, which can increase volatility if that sector faces downturns or regulatory pressures.
NXTE vs. SPDR S&P 500 ETF (SPY)
- AUM
- 50.08M
- Region
- Global
- Expense Ratio
- 1.00%
- Beta
- 1.24
- Issuer
- AXS Investments
- Inception Date
- Sep 27, 2022
- Dividend Yield
- 0.57%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
NXTE Summary
AXS Green Alpha ETF (NXTE) is a theme-based fund that focuses on companies driving environmental innovation and sustainable growth, rather than tracking a traditional index. It mainly invests in U.S. businesses across technology, healthcare, and other sectors, with top holdings like TSMC and IBM. Someone might consider NXTE to gain exposure to green technology and renewable-focused companies, aiming for long-term growth while supporting sustainability. However, this ETF can be volatile and is heavily tilted toward tech and other innovative industries, so its value can go up and down more than the broader market.
How much will it cost me?
This ETF has an expense ratio of 1.00%, which means you’ll pay about $10 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed and focused on a specialized green, thematic strategy, which typically costs more to run than broad, passive index funds.
What would affect this ETF?
NXTE could benefit if global demand for green technology and renewable energy keeps growing, especially since it is heavily invested in innovative chipmakers like TSMC and ASML and health care names focused on advanced treatments. On the downside, higher interest rates, stricter regulations on technology or biotech, trade tensions affecting global semiconductor supply chains, or a slowdown in economic growth could hurt these holdings and increase volatility for this globally focused thematic ETF.
NXTE Top 10 Holdings
NXTE is leaning heavily into the global semiconductor boom, with TSMC and SK hynix acting as the main engines of performance. TSMC has been rising steadily, while SK hynix has seen more mixed, recently lagging action, creating a bit of push-and-pull in returns. ASML, Applied Materials, and Lam Research add more chip-making firepower, keeping the fund firmly anchored in green-tinged tech hardware. On the health side, Moderna has been a bright spot, surging lately and helping offset weaker names like IBM and Crispr Therapeutics. Overall, it’s a globally focused, chip-and-innovation story with a sustainability twist.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 TSM | TSMC | 11.44% | $5.50M | $1.88T | 33.94% | 81Outperform |
 KR:000660 | SK hynix Inc. | 9.65% | $4.64M | KRW 1033.53T | 149.65% | ―― |
 MRNA | Moderna | 6.02% | $2.90M | $88.52B | 687.92% | 59Neutral |
 ASML | ASML Holding | 4.61% | $2.22M | $604.74B | 45.60% | 81Outperform |
 IBM | International Business Machines | 4.57% | $2.20M | $243.66B | -16.85% | 79Outperform |
 AMAT | Applied Materials | 3.66% | $1.76M | $309.57B | 67.74% | 77Outperform |
 LRCX | Lam Research | 3.52% | $1.69M | $298.69B | 48.51% | 77Outperform |
 CRSP | Crispr Therapeutics AG | 3.29% | $1.58M | $4.97B | -15.84% | 40Underperform |
 QCOM | Qualcomm | 2.68% | $1.29M | $175.97B | -7.03% | 80Outperform |
NXTE Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For NXTE, the sentiment is Negative. The current price of 44.01 is below the 20-day moving average (MA) of 45.67, below the 50-day MA of 47.16, and below the 200-day MA of 45.60, indicating a bearish trend. The MACD of -0.88 indicates Negative momentum. The RSI at 41.41 is Neutral, neither overbought nor oversold. The STOCH value of 81.78 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NXTE.
NXTE Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| NXTE | $44.01 | $50.00(13.61% Upside) | $50.08M | 1.00% | 55Neutral |
 FFND | $31.51 | $38.57(22.41% Upside) | $96.42M | 0.98% | 66Neutral |
 IQM | $93.13 | $139.53(49.83% Upside) | $79.04M | 0.50% | 69Neutral |
 DARP | $53.47 | $74.48(39.29% Upside) | $41.12M | 0.75% | 71Outperform |
 FIZY | $26.29 | $31.56(20.04% Upside) | $14.70M | 1.01% | 75Outperform |
 GAIQ | $63.43 | $80.74(27.28% Upside) | $645.90K | 0.79% | 75Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NXTE | AXS Green Alpha ETF | 44.01 | 3.63 | 9.00% | |
| FFND | Future Fund Active ETF | 31.50 | 1.47 | 4.89% | |
| IQM | Franklin Intelligent Machines ETF | 93.13 | -2.44 | -2.55% | |
| DARP | Grizzle Growth Etf | 53.47 | 7.85 | 17.20% | |
| FIZY | Fitz-Gerald Must Have Portfolio and Options Overlay ETF | 26.29 | 1.15 | 4.59% | |
| GAIQ | Guinness Atkinson Global Innovators Fund: ETF Class Shares | 63.43 | -1.42 | -2.19% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.